Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.39 CAD
Change Today +0.14 / 11.20%
Volume 1.7M
TH On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 5:00 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

theratechnologies inc (TH) Snapshot

Open
C$1.24
Previous Close
C$1.25
Day High
C$1.47
Day Low
C$1.23
52 Week High
04/20/15 - C$1.47
52 Week Low
12/3/14 - C$0.33
Market Cap
84.8M
Average Volume 10 Days
920.8K
EPS TTM
C$-0.13
Shares Outstanding
61.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERATECHNOLOGIES INC (TH)

Related News

No related news articles were found.

theratechnologies inc (TH) Related Businessweek News

No Related Businessweek News Found

theratechnologies inc (TH) Details

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs in metabolic disorders. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. The company was founded in 1993 and is headquartered in Montreal, Canada.

19 Employees
Last Reported Date: 02/26/15
Founded in 1993

theratechnologies inc (TH) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$376.0K
Vice President of Finance
Total Annual Compensation: C$170.0K
Vice President of Legal Affairs and Corporate...
Total Annual Compensation: C$233.0K
Vice President of Pharmaceutical Development
Total Annual Compensation: C$211.5K
Senior Vice President of Scientific Affairs a...
Total Annual Compensation: C$265.0K
Compensation as of Fiscal Year 2013.

theratechnologies inc (TH) Key Developments

Theratechnologies Inc. Announces Supreme Court of Canada Rules in its Favour, Shareholder Class Action Motion Denied

Theratechnologies Inc. announced that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc.'s motion for leave to commence an action based on the secondary market liability provisions of the Securities Act (Quebec) against Theratechnologies. The judgment reverses the July 17, 2013 decision of the Court of Appeal of Quebec confirming the February 24, 2012 decision issued by the Superior Court of Quebec, which authorized 121851 Canada Inc., the representative of persons who were shareholders on May 21, 2010 and who sold their common shares of the Company on May 25 or 26, 2010, to institute a class action against the Company. The shareholder had claimed that Theratechnologies had failed to disclose a material change as a reporting issuer and that such failure had resulted in damage.

Theratechnologies Inc. Announces Consolidated Earnings Results for the First Quarter Ended February 28, 2014

Theratechnologies Inc. announced consolidated earnings results for the first quarter ended February 28, 2014. For the quarter, the company reported revenue was CAD 4,571,000 compared to CAD 1,672,000 in the comparable period of 2014. Revenue generated by net sales amounted to CAD 4,567,000 in the three-month period ended February 28, 2015 compared to CAD 675,000 in the comparable period of fiscal 2014. The significant increase is principally due to the changes in the company's business model as explained above. Finance income was CAD 258,000 compared to CAD 105,000 in the comparable period of fiscal 2014. Interest revenue has decreased due to a gradual decline in the portfolio size as investments are liquidated to fund operations. Net loss of CAD 914,000 or CAD 0.01 per share in the three months ended February 28, 2015 compared to a net loss of CAD 3,534,000 or CAD 0.06 per share in the comparable period of fiscal 2014. In the three-month period ended February 28, 2015, operating activities generated positive cash flow of CAD 720,000, a significant improvement over in the comparable period of 2014 when cash flow from operating activities was negative CAD 2,305,000. Loss from operating activities for the first quarter ended February 28, 2015 was CAD 726,000, compared to a loss from operating activities of CAD 3.6 million for the same quarter ended February 28, 2014. Loss before income taxes for the first quarter ended February 28, 2015 was CAD 904,000, compared to a loss before income taxes of CAD 3.53 million for the same quarter ended February 28, 2014.

Theratechnologies Inc. to Report Q1, 2015 Results on Apr 14, 2015

Theratechnologies Inc. announced that they will report Q1, 2015 results Pre-Market on Apr 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TH:CN C$1.39 CAD +0.14

TH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TH.
View Industry Companies
 

Industry Analysis

TH

Industry Average

Valuation TH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERATECHNOLOGIES INC, please visit www.theratech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.